Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study | Future Oncology
Safety and management of niraparib monotherapy in ovarian cancer clinical trials | International Journal of Gynecologic Cancer
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count : results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Current Oncology | Free Full-Text | A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
Use of First-Line PARP Inhibitors in Ovarian Cancer | Published in healthbook TIMES Oncology Hematology
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
Niraparib in the PRIMA Trial
Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
First-line niraparib is associated with improvement in QA-PFS and QA-TWiST
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
The latest clinical evidence on PARP inhibitor maintenance therapy - ppt download
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Efficacy | ZEJULA (niraparib) for HCPs
